|
1
|
Thompson MR, Xu D and Williams BR: ATF3
transcription factor and its emerging roles in immunity and cancer.
J Mol Med (Berl). 87:1053–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yin X, Dewille JW and Hai T: A potential
dichotomous role of ATF3, an adaptive-response gene, in cancer
development. Oncogene. 27:2118–2127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pelzer AE, Bektic J, Haag P, Berger AP,
Pycha A, Schäfer G, Rogatsch H, Horninger W, Bartsch G and Klocker
H: The expression of transcription factor activating transcription
factor 3 in the human prostate and its regulation by androgen in
prostate cancer. J Urol. 175:1517–1522. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janz M, Hummel M, Truss M, Wollert-Wulf B,
Mathas S, Jöhrens K, Hagemeier C, Bommert K, Stein H, Dörken B and
Bargou RC: Classical Hodgkin lymphoma is characterized by high
constitutive expression of activating transcription factor 3
(ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells.
Blood. 107:2536–2539. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK,
Wang Q, Wang X and Wong YC: Overexpression of Id-1 in prostate
cancer cells promotes angiogenesis through the activation of
vascular endothelial growth factor (VEGF). Carcinogenesis.
26:1668–1676. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bandyopadhyay S, Wang Y, Zhan R, Pai SK,
Watabe M, Iiizumi M, Furuta E, Mohinta S, Liu W, Hirota S, et al:
The tumor metastasis suppressor gene Drg-1 down-regulates the
expression of activating transcription factor 3 in prostate cancer.
Cancer Res. 66:11983–11990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maytin EV, Ubeda M, Lin JC and Habener JF:
Stress-inducible transcription factor CHOP/gadd153 induces
apoptosis in mammalian cells via p38 kinase-dependent and
-independent mechanisms. Exp Cell Res. 267:193–204. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan X, Yu L, Li J, Xie G, Rong T, Zhang
L, Chen J, Meng Q, Irving AT, Wang D, et al: ATF3 suppresses
metastasis of bladder cancer by regulating gelsolin-mediated
remodeling of the actin cytoskeleton. Cancer Res. 73:3625–3637.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jan YH, Tsai HY, Yang CJ, Huang MS, Yang
YF, Lai TC, Lee CH, Jeng YM, Huang CY, Su JL, et al: Adenylate
kinase-4 is a marker of poor clinical outcomes that promotes
metastasis of lung cancer by downregulating the transcription
factor ATF3. Cancer Res. 72:5119–5129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei S, Wang H, Lu C, Malmut S, Zhang J,
Ren S, Yu G, Wang W, Tang DD and Yan C: The activating
transcription factor 3 protein suppresses the oncogenic function of
mutant p53 proteins. J Biol Chem. 289:8947–8959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang Y, Chen CR and Massague J: A
self-enabling TGFbeta response coupled to stress signaling: Smad
engages stress response factor ATF3 for Id1 repression in
epithelial cells. Mol Cell. 11:915–926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bottone FG Jr and Alston-Mills B: The
dietary compounds resveratrol and genistein induce activating
transcription factor 3 while suppressing inhibitor of DNA
binding/differentiation-1. J Med Food. 14:584–593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perk J, Iavarone A and Benezra R: Id
family of helix-loop-helix proteins in cancer. Nat Rev Cancer.
5:603–614. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benezra R, Davis RL, Lockshon D, Turner DL
and Weintraub H: The protein Id: A negative regulator of
helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patel D, Morton DJ, Carey J, Havrda MC and
Chaudhary J: Inhibitor of differentiation 4 (ID4): From development
to cancer. Biochim Biophys Acta. 1855:92–103. 2014.PubMed/NCBI
|
|
16
|
Castanon E, Bosch-Barrera J, López I,
Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A
and Gil-Bazo I: Id1 and Id3 co-expression correlates with clinical
outcome in stage III-N2 non-small cell lung cancer patients treated
with definitive chemoradiotherapy. J Transl Med. 11:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang R, Hirsch P, Fava F, Lapusan S,
Marzac C, Teyssandier I, Pardo J, Marie JP and Legrand O: High Id1
expression is associated with poor prognosis in 237 patients with
acute myeloid leukemia. Blood. 114:2993–3000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schoppmann SF, Schindl M, Bayer G, Aumayr
K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R and Birner P:
Overexpression of Id-1 is associated with poor clinical outcome in
node negative breast cancer. Int J Cancer. 104:677–682. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kashiwakura Y, Ochiai K, Watanabe M,
Abarzua F, Sakaguchi M, Takaoka M, Tanimoto R, Nasu Y, Huh NH and
Kumon H: Down-regulation of inhibition of differentiation-1 via
activation of activating transcription factor 3 and Smad regulates
REIC/Dickkopf-3-induced apoptosis. Cancer Res. 68:8333–8341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan H, Zhang H, Xie J, Chen B, Wen C, Guo
X, Zhao Q, Wu Z, Shen J, Wu J, et al: A novel staging model to
classify oesophageal squamous cell carcinoma patients in China. Br
J Cancer. 110:2109–2115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie JJ, Xie YM, Chen B, Pan F, Guo JC,
Zhao Q, Shen JH, Wu ZY, Wu JY, Xu LY and Li EM: ATF3 functions as a
novel tumor suppressor with prognostic significance in esophageal
squamous cell carcinoma. Oncotarget. 5:8569–8582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li T, Yang W, Li M, Byun DS, Tong C,
Nasser S, Zhuang M, Arango D, Mariadason JM and Augenlicht LH:
Expression of selenium-binding protein 1 characterizes intestinal
cell maturation and predicts survival for patients with colorectal
cancer. Mol Nutr Food Res. 52:1289–1299. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bi X, Pohl NM, Qian Z, Yang GR, Gou Y,
Guzman G, Kajdacsy-Balla A, et al: Decorin-mediated inhibition of
colorectal cancer growth and migration is associated with
E-cadherin in vitro and in mice. Carcinogenesis. 33:326–330. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang LD, Zhou FY, Li XM, Sun LD, Song X,
Jin Y, Li JM, Kong GQ, Qi H, Cui J, et al: Genome-wide association
study of esophageal squamous cell carcinoma in Chinese subjects
identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet.
42:759–763. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abnet CC, Freedman ND, Hu N, Wang Z, Yu K,
Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, et al: A shared
susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma
and esophageal squamous cell carcinoma. Nat Genet. 42:764–767.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y,
Liu Z, Zhan Q, Liu Y, Yu D, et al: Genome-wide association study
identifies three new susceptibility loci for esophageal
squamous-cell carcinoma in Chinese populations. Nat Genet.
43:679–684. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu C, Wang Z, Song X, Feng XS, Abnet CC,
He J, Hu N, Zuo XB, Tan W, Zhan Q, et al: Joint analysis of three
genome-wide association studies of esophageal squamous cell
carcinoma in Chinese populations. Nat Genet. 46:1001–1006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shtutman M, Zhurinsky J, Simcha I,
Albanese C, et al: The cyclin D1 gene is a target of the
beta-catenin/LEF-1 pathway. PNAS U.S.A. 96:5522–5527. 1999.
View Article : Google Scholar
|
|
31
|
Wu S, Bao Y, Ma D, Zi Y, et al: Sodium
selenite inhibits leukemia HL-60 cell proliferation and induces
cell apoptosis by enhancing the phosphorylation of JNK1 and
increasing the expression of p21 and p27. Int J Mol Med.
34:1175–1179. 2014.PubMed/NCBI
|
|
32
|
Okumura H, Uchikado Y, Setoyama T,
Matsumoto M, Owaki T, Ishigami S and Natsugoe S: Biomarkers for
predicting the response of esophageal squamous cell carcinoma to
neoadjuvant chemoradiation therapy. Surg Today. 44:421–428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Quante M, Varga J, Wang TC and Greten FR:
The gastrointestinal tumor microenvironment. Gastroenterology.
145:63–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Doki Y, Shiozaki H, Tahara H, Inoue M, Oka
H, Iihara K, Kadowaki T, Takeichi M and Mori T: Correlation between
E-cadherin expression and invasiveness in vitro in a human
esophageal cancer cell line. Cancer Res. 53:3421–3426.
1993.PubMed/NCBI
|
|
36
|
Oka H, Shiozaki H, Kobayashi K, Inoue M,
Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S,
Takeichi M, et al: Expression of E-cadherin cell adhesion molecules
in human breast cancer tissues and its relationship to metastasis.
Cancer Res. 53:1696–1701. 1993.PubMed/NCBI
|
|
37
|
Umbas R, Isaacs WB, Bringuier PP,
Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken
JA: Decreased E-cadherin expression is associated with poor
prognosis in patients with prostate cancer. Cancer Res.
54:3929–3933. 1994.PubMed/NCBI
|
|
38
|
Derksen PW, Liu X, Saridin F, van der
Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink
J, Krimpenfort P, et al: Somatic inactivation of E-cadherin and p53
in mice leads to metastatic lobular mammary carcinoma through
induction of anoikis resistance and angiogenesis. Cancer Cell.
10:437–449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Frixen UH, Behrens J, Sachs M, Eberle G,
Voss B, et al: E-cadherin-mediated cell-cell adhesion prevents
invasiveness of human carcinoma cells. J Cell Biol. 113:173–185.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baranwal S and Alahari SK: Molecular
mechanisms controlling E-cadherin expression in breast cancer.
Biochem Biophys Res Commun. 384:6–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang CC and Wolf DA: Inflamed snail speeds
metastasis. Cancer Cell. 15:355–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
